<DOC>
	<DOCNO>NCT02828241</DOCNO>
	<brief_summary>The purpose exploratory study ass efficacy , safety tolerability DFD-04 Ointment topical treatment rosacea 12 week treatment .</brief_summary>
	<brief_title>A Study Assess Efficacy , Safety Tolerability DFD-04</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>1 . Subjects must able understand requirement study willing give write informed consent . 2 . Subjects must willing provide authorization use protect health information . 3 . Subjects , gender race , must good general health determine Investigator 4 . Subjects must clinical diagnosis papulopustular rosacea , Investigator 's Global Assessment ( IGA ) grade 2 3 . 5 . Subjects must 6 30 inflammatory lesion ( papule pustule ) rosacea face . 6 . Subjects must Clinician ` Erythema Assessment ( CEA ) score 2 3 . 7 . Subjects must 2 nodule . 8 . Subjects must agree use study product use treatment rosacea ( prescription counter ) skin care cosmetic product ( makeup etc . ) facial skin treatment area course study . 9 . Subjects must free systemic dermatologic disorder , opinion Investigator , interfere study result . 10 . Females negative urine pregnancy test Screening Baseline Visit . 11 . Females must either postmenopausal menses least 12 month surgically sterile ( hysterectomy tubal ligation ) agree use reliable method contraception failure rate le 1 percent per year use consistently correctly . 12 . Subject must good general health determine investigator support medical history normal clinically significant abnormal vital sign ( blood pressure pulse ) . 13 . Subject physically able apply study product affect area . 1 . Females pregnant nursing planning become pregnant study . 2 . Subjects treat rosacea within 30 day prior Baseline Visit . 3 . Subjects treat systemic retinoids within 6 month prior Baseline visit . 4 . Subjects participate trial involve investigational product 30 day prior Baseline Visit . 5 . Subjects disease medical condition would interfere study place subject undue risk especially cardiovascular disease , reduce lung function ( include asthma ) , renal dysfunction liver dysfunction . 6 . Subjects treat within 30 day prior baseline visit methadone , disopyramide , dofetilide , dronedarone , quinidine , ergot alkaloid ( dihydroergotamine , ergometrine ( ergonovine ) , ergotamine , methylergometrine ( methylergonovine ) ) , irinotecan , lurasidone , oral midazolam , pimozide , triazolam , felodipine , nisoldipine , ranolazine , eplerenone , cisapride , lovastatin , simvastatin , ticagrelor , terfenadine , astemizole , mizolastine , eletriptan , well lovastatin , simvastatin atorvastatin , subject vary degree renal hepatic impairment , colchicine , fesoterodine , telithromycin solifenacin . 7 . Subjects use use systemic steroid within 30 day prior Baseline Visit immunosuppressive medication . 8 . Subjects positive human immunodeficiency virus ( HIV ) , hepatitis B hepatitis Ctest screening . 9 . Subjects unable comply study requirement . 10 . Subjects skin disease may confound evaluation rosacea . 11 . History organ transplant require immunosuppression , HIV , immune compromise state . 12 . Subject opinion investigator physician perform initial examination subject participate trial , e.g . due probable noncompliance inability understand trial give adequately inform consent 13 . Subject close affiliation investigator ( e.g . close relative ) person work respective trial site subject employee sponsor . 14 . Subject institutionalized legal regulatory order . 15 . History drug alcohol abuse last year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>